Press Releases
Company News
View Summary Medivation Names Andrew Powell General Counsel
May 28, 2015
PDF 10.3 KB Add to Briefcase
View Summary Medivation and Astellas Announce New Enzalutamide Data Presented at the 2015 American Urology Association Annual Meeting
May 17, 2015
PDF 157.9 KB Add to Briefcase
View Summary New Enzalutamide Data in Triple-Negative Breast Cancer to Be Presented at the 2015 ASCO Annual Meeting
May 14, 2015
PDF 153.4 KB Add to Briefcase
View Summary Medivation Reports First Quarter 2015 Financial Results
May 7, 2015
PDF 181.1 KB Add to Briefcase
View Summary New Enzalutamide Data to Be Presented in Late Breaking Plenary Session at AUA Annual Meeting
May 5, 2015
PDF 155.6 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
May 4, 2015
PDF 9.1 KB Add to Briefcase
View Summary Medivation Announces First Quarter 2015 Financial Results Teleconference on May 7, 2015
Apr 23, 2015
PDF 9.1 KB Add to Briefcase
View Summary Enzalutamide Demonstrates Statistically Significant Improvement in Progression Free Survival Compared With Bicalutamide in Strive Trial
Apr 2, 2015
PDF 156.4 KB Add to Briefcase
View Summary Medivation and Astellas Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress
Mar 24, 2015
PDF 162.9 KB Add to Briefcase
View Summary New Enzalutamide Data to Be Presented in Late Breaking News Plenary Session at European Association of Urology Congress
Mar 16, 2015
PDF 156.2 KB Add to Briefcase
View Summary Medivation Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
Feb 25, 2015
PDF 182.7 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Feb 24, 2015
PDF 9.1 KB Add to Briefcase
View Summary Medivation Announces Fourth Quarter and Year-End 2014 Financial Results Teleconference on February 25, 2015
Feb 11, 2015
PDF 9.2 KB Add to Briefcase
View Summary Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compared to Bicalutamide in Metastatic Prostate Cancer
Jan 22, 2015
PDF 156.1 KB Add to Briefcase
View Summary Medivation Exercises License Option for Pidilizumab
Dec 22, 2014
PDF 9.9 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Dec 17, 2014
PDF 9.3 KB Add to Briefcase
View Summary Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer
Dec 12, 2014
PDF 160.3 KB Add to Briefcase
View Summary Phase 3 PREVAIL Trial Named Clinical Advance of the Year by SCRIP
Dec 10, 2014
PDF 156.0 KB Add to Briefcase
View Summary Joseph Lobacki to Become Medivation's Chief Commercial Officer
Nov 25, 2014
PDF 9.7 KB Add to Briefcase
View Summary Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner
Nov 17, 2014
PDF 10.6 KB Add to Briefcase
Showing 1-20 of 330 Page: 1 2 3 4 5 ... 17  Next 20
Add to Briefcase = add release to Briefcase

Top